Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
INCY Logo

Incyte Corp

INCY

Services-Commercial Physical & Biological Research

Mkt Cap

$11.81B

PE

27.78

Debt

-

Cash

$3.229B

EV

-

FCF

$580.9M

Market Cap

$11.81B

P/E Ratio

27.78

Debt

-

Cash

$3.229B

EV

-

FCF

$580.9M

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Sector

  • CRL Logo

    CRL

  • IQV Logo

    IQV

  • MEDP Logo

    MEDP

  • MXCT Logo

    MXCT

  • NRC Logo

    NRC

  • OABI Logo

    OABI

Growth

%

%

Discount

%

%

Multiple

g\r+10%+11%+12%+13%+14%
0%109887
+1%1110988
+2%13111098
+3%141311109
+4%1714121110
Years012345678910TV
FCF$580.9M$755.2M$960.8M$1.196B$1.455B$1.729B$2.008B$2.276B$2.516B$2.712B$2.847B$28.47B
DCF$656.7M$726.5M$786.2M$831.7M$859.9M$868.2M$855.6M$822.5M$770.9M$703.8M$7.038B
Value$14.92B

In the chart Earnings are multiplied by this value.

Earnings Growth 49%
Earnings Stability 21%


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12-201412-201512-201612-201712-201812-201912-202012-202112-2022TTM
Net Margin-9.5%0.87%9.4%-20%5.8%21%-11%32%10%12%
ROA-0.21%5.3%8.9%-11%4.9%14%-6.5%12%9.9%9.9%
ROE59%3.8%25%-19%5.7%17%-11%25%7.8%8.6%

What is the average Net Margin?

The average Net Margin over the past 5 years is +6.14%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is +5.66%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is +3.98%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +2.94%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is +4.22%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +4.71%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12-201412-201512-201612-201712-201812-201912-202012-202112-2022TTM
Debt FCF-944.4611.834.06-0.1772.670.03----
Debt Equity-18.744.381.790.029.910.01----
MIN
Graham Stability----1.5K%---360%100%93%-1.5K%

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is 0.10.

What is the Graham’s Stability?

Graham’s Stability measure stands at -15.09.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12-201512-201712-201912-2021Trend
Revenue24%17%16%14%-5%
Net Income76%--8.7%-64%-260%
Stockholders Equity59%22%19%16%-32%
FCF46%-12%57%-22%

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is +17.18%.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -4.97%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -259.98%.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is +21.79%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -31.92%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -22.34%.